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ABSTRACT
Background
The acquired component of complex traits is difficult to dissect in humans. Obesity
represents such a trait, in which the metabolic and molecular consequences emerge from
complex interactions of genes and environment. With the substantial morbidity associated with
obesity, a deeper understanding of the concurrent metabolic changes is of considerable
importance. The goal of this study was to investigate this important acquired component and
expose obesity-induced changes in biological pathways in an identical genetic background.
Methods and Findings
We used a special study design of ‘‘clonal controls,’’ rare monozygotic twins discordant for
obesity identified through a national registry of 2,453 young, healthy twin pairs. A total of 14
pairs were studied (eight male, six female; white), with a mean 6 standard deviation (SD) age
25.8 6 1.4 y and a body mass index (BMI) difference 5.2 6 1.8 kg/m
2. Sequence analyses of
mitochondrial DNA (mtDNA) in subcutaneous fat and peripheral leukocytes revealed no
aberrant heteroplasmy between the co-twins. However, mtDNA copy number was reduced by
47% in the obese co-twin’s fat. In addition, novel pathway analyses of the adipose tissue
transcription profiles exposed significant down-regulation of mitochondrial branched-chain
amino acid (BCAA) catabolism (p , 0.0001). In line with this finding, serum levels of insulin
secretion-enhancing BCAAs were increased in obese male co-twins (9% increase, p ¼ 0.025).
Lending clinical relevance to the findings, in both sexes the observed aberrations in
mitochondrial amino acid metabolism pathways in fat correlated closely with liver fat
accumulation, insulin resistance, and hyperinsulinemia, early aberrations of acquired obesity in
these healthy young adults.
Conclusions
Our findings emphasize a substantial role of mitochondrial energy- and amino acid
metabolism in obesity and development of insulin resistance.
The Editors’ Summary of this article follows the references.
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Adipose tissue is a key player in obesity-related metabolic
dysfunctions, and is closely linked to other peripheral organs
that control energy ﬂux [1]. To understand the pathogenesis
of adipose tissue dysfunction at a molecular level, a global
view of the networks and their interactions should be more
informative than monitoring single-gene effects [2]. Expres-
sion array studies on human adipose tissue have shown that
the various inﬂammatory pathways are activated in obesity
[3,4] and are down-regulated following weight loss [5]. The
major inﬂammatory cells in fat are macrophages of different
subtypes [6,7], which scavenge adipocyte debris from necrotic
cells [8]. Paradoxically in obesity, macrophage-secreted
factors may result in impaired adipogenesis [9] by inhibiting
the expression of adipogenic transcription factors including
peroxisome proliferator-activated receptor-gamma (PPARc)
[10]. Impaired adipogenesis and defects in mitochondrial
energy metabolism in subcutaneous adipose tissue have been
suggested to shift lipid storage into ectopic insulin-sensitive
tissues such as the liver, skeletal muscle, and pancreas,
resulting in severe insulin resistance [11,12]. Induction of
adipocyte differentiation [13] and mitochondrial biogenesis
[14] in subcutaneous sites could reverse these abnormalities
[15]. However, molecular pathways related to aberrations in
adipocyte differentiation in obesity remain unknown. Fur-
thermore, although mitochondrial dysfunction has been
previously identiﬁed in muscle in human obesity and type 2
diabetes [16–18] as well as in the adipocytes of obese rodents
[19,20], direct evidence of possible defects in mitochondrial
function in adipocytes in human obesity is lacking.
Obesity-related gene expression variations in fat are
inﬂuenced by complex interactions of genes and the environ-
ment, the contributions of which are difﬁcult to disentangle.
Studying tissue samples of rare monozygotic (MZ) twin pairs
discordant for body weight provides a unique opportunity to
explore the effects of acquired obesity, since these individuals
share not only identical genetic background, but also early
life events and family environment. In this study, we utilized a
special collection of such weight-discordant MZ twins with
identical genetic background and through in-depth pheno-
typing and analysis of their global gene expression proﬁles in
adipose tissue, aimed at describing the changes in biological
pathways that accompany acquired obesity and relate these to
the associated clinically relevant aberrations.
Methods
Participants
The participants were recruited from a population-based
longitudinal study of ﬁve consecutive birth cohorts (1975–
1979) of twins, their siblings, and their parents (n ¼ 2,453
families), identiﬁed through the national population registry
of Finland [21]. Twin pairs included in the current study were
enrolled on the basis of their responses to questions on
weight and height at age 23–27 y. From this cohort, we
searched for the top 5% most obesity-discordant MZ twin
pairs (one co-twin not obese [BMI ;25 kg/m
2], and the other
one obese [BMI ;30 kg/m
2]), with no signiﬁcant height
differences (,4 cm). After screening all MZ twin pairs (n ¼
658), we identiﬁed 18 pairs above the 95th percentile of BMI
differences (3.1 kg/m
2) [22–27]. Of these pairs, 14 (eight male
and six female pairs) were willing to participate, and 13 pairs
(eight male and ﬁve female pairs, BMI differences 3.3–10.0 kg/
m
2, height differences ,3 cm) had adipose tissue samples
available for the present study. All pairs were researcher-
designated white, and their mean age was 25.8 6 1.4 y. The
participants were healthy (based on medical history, clinical
examination, and structured psychiatric interview), normo-
tensive, and did not use any medications except oral
contraceptives. Their weights had been stable for at least 3
mo prior to the study. Females were scheduled to attend
during the follicular phase of their menstrual cycle. Mono-
zygosity was conﬁrmed by genotyping of ten informative
genetic markers [23]. The participants provided written
informed consent. The protocol was designed and performed
according to the principles of the Helsinki Declaration and
was approved by the Ethical Committee of the Helsinki
University Central Hospital.
Study Design
The study design is shown in Figure 1. A more detailed
description of methods is provided in Text S1. In brief, all
participants were studied starting at 8 A.M. after an overnight
fast. Venous blood samples were obtained and plasma with
EDTA and serum were separated by centrifugation and
stored at  80 8C until the analyses of insulin, adiponectin,
leptin, high-sensitivity CRP, leucine, valine, and isoleucine,
and a leucine breakdown product, a-ketoisocaproate. Whole-
body insulin sensitivity (the M-value, measured in mg kg fat-
free mass
 1 min
 1) was measured using the euglycemic–
hyperinsulinemic clamp technique [28]. Body composition
was measured by dual-energy x-ray absorptiometry (DEXA),
subcutaneous and intra-abdominal fat by MRI of 16 transaxial
scans reaching from 8 cm above to 8 cm below the fourth and
ﬁfth lumbar interspace, and liver fat content by proton
spectroscopy [22].
Fat cell size was determined from fresh subcutaneous
abdominal adipose tissue samples treated with collagenase.
RNA was prepared from frozen fat and used for the global
gene expression analyses in Affymetrix U133 Plus 2.0 chips.
Affymetrix gene expression chip data were analyzed using
MAS-5 according to the manufacturer’s recommendations,
and preprocessed with the GC-RMA algorithm. Given the
unique setup involving MZ twins, the expression data were
further ‘‘co-twin normalized,’’ which involved dividing the
obese twin’s expression values with those of the non-obese co-
twin in order to correct for the identical genetic background.
The pathway analysis was done with an in-house nonpara-
metric analysis algorithm utilizing the Gene Ontology (GO)
categories (previously used in [29–32]), in which the objective
is to ﬁnd the optimal regulated pathway compositions
without a priori criteria for signiﬁcance for individual genes’
signiﬁcant regulation or arbitrary p-value/fold change cut-
offs. The method uses an iterative cumulative hypergeometric
distribution p-value–based calculation, and empirical p-values
reported are interpreted from the distribution of 10,000
permutation cycles as described in Text S1. As a feature of
the tree-like structure of the GO classiﬁcations, gene sets get
progressively larger and less descriptive when moving down
the tree. Therefore, in order to concentrate on the bio-
logically more meaningful pathway collections, an arbitrary
cut-off of a maximum of 250 genes was chosen as the largest
reported gene list.
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normalized against a nuclear single-copy gene, by ampliﬁca-
tion of the cytB gene from mtDNA and APP from nuclear
DNA, from total DNA extracted from adipose tissue and
leukocyte samples. Real-time PCR with TaqMan probes was
utilized, and quantitation was performed in the exponential
ampliﬁcation phase. The full mitochondrial DNA sequences
were determined from extracted total DNAs by high-
throughput mtDNA sequence analyses utilizing ampliﬁcation
of mtDNA in two large fragments, followed by DNA
sequencing with several internal primers, as speciﬁed in Text
S1.
Statistical Analyses
The statistical analyses of the clinical parameters were
performed using Stata statistical software (release 8.0; Stata
Corporation). Between–co-twin comparisons were made by
paired Wilcoxon signed ranks test. Male and female pairs
were combined because, by deﬁnition, MZ co-twins are
matched for gender. Within pairs, Spearman correlation
was used to test the effects of the extent of BMI discordance
on gene expression pathways. In individual twins, Pearson
correlation and multiple regression analyses, corrected for
clustered sampling of co-twins by survey methods [33], were
performed to determine the relationships between gene
expression and clinical characteristics. The survey commands
in Stata require the use of parametric tests. Log-trans-
formation was used to normalize the distribution of liver fat
and serum adiponectin.
Results
Clinical Characteristics of the Obesity-Discordant
Monozygotic Co-twins
The obese co-twins of the pairs discordant for obesity were
on average 15.2 kg (20%) heavier than the non-obese co-twins
(Table 1). This weight discordance had developed in
postpubertal adolescence and thus represented early obesity
[23]. While a marginal difference in birth weight could be
observed, this had no correlation with any adult measures of
obesity. Dietary intake of energy, protein, carbohydrate, or
total fat did not differ between the co-twins, but the obese co-
twins consumed less mono- and polyunsaturated fatty acids
[22]. Physical activity at the time of the study and in late
adolescence was lower in the obese co-twins [34]. Using
detailed body composition measurements (DEXA, MRI, and
spectroscopy), we could deﬁne the difference in total body fat
and its distribution in these twin pairs. The obese co-twins
had more fat subcutaneously, intra-abdominally, and in the
liver (Table 1). They also had signiﬁcantly larger fat cells. The
obese co-twins’ whole body insulin sensitivity (the M-value)
and fasting serum adiponectin concentrations were signiﬁ-
Figure 1. Study Design and the Global Transcript Profiles in Subcutaneous Fat in the Co-twins
doi:10.1371/journal.pmed.0050051.g001
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their co-twins. The differences within the pairs were similar
for males and females. All measurements of insulin sensitivity
correlated closely with liver fat in the individual twins (M-
value r¼ 0.65, p¼0.001; adiponectin r¼ 0.50, p¼0.009; and
fasting serum (fS)-insulin r¼0.65, p¼0.001). The correlations
between insulin sensitivity and subcutaneous and intra-
abdominal fat were slightly lower (e.g., the correlation
between fS-insulin and subcutaneous fat was r ¼ 0.45, p ¼
0.016 and that between fS-insulin and intra-abdominal fat r¼
0.47, p ¼ 0.013.).
Transcript Profiles Reveal Significant Changes in the
Obese Co-twins
Recent studies integrating expression proﬁling with linkage
analysis have shown that the single most important determi-
nant for global transcript proﬁles in rodent fat is gender [35].
This pattern was also evident in our non-supervised cluster-
ing analyses, in which the transcription proﬁles of the fat
biopsies were clustered according to gender (unpublished
data). The method we used to normalize the global expression
values of each MZ twin to their co-twin (twin normalization)
not only eliminated the genetic component, but also
corrected for between-gender differences of the variance in
transcript levels [36]. Following normalization, the samples no
longer exhibited clustering by gender.
The volcano plot in Figure 1 shows many similarities but
also signiﬁcant differences in the transcription proﬁles
between the obese and non-obese twins. We used here an
in-house–designed nonparametric analysis algorithm for
discovering more subtly regulated pathways. The Gene
Ontology (GO) classiﬁcations were used to explore the
pathways that were signiﬁcantly different between the obese
and non-obese co-twins. After pathways with more than 250
genes were ﬁltered off, 19 up-regulated (Tables 2 and S1) and
seven down-regulated pathways (Tables 3 and S2) were
identiﬁed in the obese co-twins.
Inflammation and Cytoskeleton Pathways Up-regulated in
the Fat of Obese Co-twins
Of the 19 up-regulated pathways, 15 were related to
inﬂammation and the rest involved organization of the
cytoskeleton (actin cytoskeleton, nominal/empirical p ¼ 3.3
3 10
 9/,1.0  3 10
 4), cell growth (growth factor binding, p ¼
1.6 3 10
 6/2.0 3 10
 5), and intracellular transport (endosome
transport, p ¼ 2.0 3 10
 6/2.0 3 10
 5 and exocytosis, p ¼ 2.2 3
10
 6/1.0 3 10
 5) (Tables 2 and S1). Both innate and adaptive
immune systems showed activation in the obesity-induced
inﬂammation cascades. Several cytokines speciﬁc for innate
immune cells, mainly macrophages (e.g., MCP-1, MCP-2, MIP-
1alpha-R, MIP-4, MIR-10)b u ta l s od e n d r i t i c( CLEC7A,
TNFSF13B) and killer cells (KLRB1) were present in the up-
regulated pathways. The complement system, both the
components of the classic pathway (complement C1 [C1S,
Table 1. Physical and Biochemical Characteristics of the Obesity-Discordant Monozygotic Twin Pairs (n ¼ 14)
Measure Obese Co-twins Non-obese Co-twins p-Value
a
Birth weight (g)
b 2,700 (2,425–2,860) 2,580 (2,160–2,770) 0.0546
Birth length (cm)
b 48 (46–48) 48 (45–49) 0.40
BMI at birth (kg/m
2)
b 12.0 (11.5–13.0) 11.3 (10.1–12.5) 0.087
BMI at 16 y (kg/m
2) 21.8 (21.2–22.2) 21.6 (20.9–22.3) 0.98
BMI at 18 y (kg/m
2) 23.7 (22.3–24.7) 22.7 (21.7–24.6) 0.10
BMI change from 16 y (kg/m
2) 8.7 (7.8–10.2) 3.8 (3.3–5.0) 0.001
Total energy expenditure (kJ/24 h)
c 12,530 (12,050–13,450) 10,730 (9,570–13,670) 0.18
Resting energy expenditure (kJ/24 h) 7,160 (5,864–7,698) 6,387 (5,763–7,244) 0.0063
Protein oxidation (mg / kg fat-free mass   min) 1.1 (0.8–1.2) 1.0 (0.8–1.0) 0.40
Carbohydrate oxidation (mg / kg fat-free mass   min) 0.8 (0–1.7) 0.5 (0–1.7) 0.51
Lipid oxidation (mg / kg fat-free mass   min) 1.6 (1.1–1.9) 1.4 (1.2–2.0) 0.55
BMI (kg/m
2) 31.1 (29.2–32.5) 25.6 (24.8–26.1) 0.0010
Percent body fat 38.3 (32.6–43.0) 28.5 (23.3–38.5) 0.0010
Subcutaneous fat (cm
3) 5,253 (4,376–5,967) 2,892 (2,430–3,966) 0.0010
Intra-abdominal fat (cm
3) 1,010 (827–1,183) 527 (380–685) 0.0010
Liver fat (%) 4.4 (2.0–11.0) 1.3 (1.0–2.5) 0.0011
Fat cell size (lm) 103.4 (95.5–108.3) 86.3 (84.5–91.5) 0.0015
Serum insulin (mU/l) 9 (6–11) 5 (3–8) 0.019
M-value (mg kg fat-free mass
 1 min
 1) 5.9 (4.5–7.0) 8.9 (7.6–10.4) 0.0058
Serum adiponectin (lg/ml)
b 9.9 (6.8–12.6) 11.9 (9.0–14.9) 0.028
Serum high sensitivity CRP (mg/l)
b 2.2 (0.9–3.4) 0.9 (0.7–1.1) 0.0051
Serum leptin (ng/ml)
b 26.5 (19.6–39.1) 16.0 (7.2–25.3) 0.0051
Serum leucine (lM) 0.145 (0.129–0.161) 0.132 (0.125–0.141) 0.17
Serum isoleucine (lM) 0.087 (0.071–0.095) 0.083 (0.074–0.088) 0.88
Serum valine (lM) 0.224 (0.206–0.242) 0.206 (0.197–0.221) 0.056
Serum a-ketoisocaproate (lmol/l) 57.2 (48.6–70.8) 61.4 (56.0–71.3) 0.51
Mitochondrial copy number in fat
d 1742 (909–2,690) 3262 (1,686–1,826) 0.033
Mitochondrial copy number in leukocytes 318 (164–416) 275 (102–380) 0.72
Data are median (interquartile range).
aObese versus non-obese co-twins, paired Wilcoxon test.
bn ¼ 10 pairs.
cn ¼ 7 pairs.
dn ¼ 11 pairs
doi:10.1371/journal.pmed.0050051.t001
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(C3/C5 convertase [CFB]) were up-regulated in the obese co-
twins. An overexpression of MHC class II molecules was also
observed, providing some basis for a hypothesis that
recognition of antigens by lymphocytes (cells of the adaptive
immunity), would be involved in obesity. T cell-speciﬁc
cytokines (CCL5, CXCL9) and their receptors (IL1R2, IL1RN)
were found in the up-regulated pathways as well as a few signs
of B cell activation (TNFSF13B).
The most overexpressed gene (5.9-fold) in the obese co-
twins was osteopontin (SPP1), a Th1 cytokine, which is
involved in macrophage recruitment and stimulation of T
cell proliferation during inﬂammation [37]. It was a constit-
uent of seven different inﬂammatory pathways in the
hierarchically clustered GO tree (Table S1). Expression of
SPP1 was signiﬁcantly correlated with liver fat (r ¼ 0.42) and
fS-insulin (r ¼ 0.43) (both p , 0.05), suggesting a role in the
pathogenesis of insulin resistance syndrome, including non-
alcoholic fatty liver disease.
The average activity of the regulated part of the whole
pathway, expressed as the mean centroid (Text S1) [16], was
used to test for correlations between the pathway ‘‘activity’’
and clinical characteristics. Inﬂammation pathways corre-
lated closely with measures of adiposity, insulin resistance,
and low-grade inﬂammation, e.g., the inﬂammatory response
pathway correlated with subcutaneous (r ¼ 0.57), intra-
abdominal (r ¼ 0.61), and liver fat (r ¼ 0.60) (all p   0.002);
the M-value (r¼ 0.45); adiponectin (r¼ 0.56); fS-insulin (r¼
0.56); and high-sensitivity C-reactive protein (CRP) (r ¼ 0.38)
(all p   0.01).
Mitochondrial Branched Chain Family Amino Acid
Catabolism Down-regulated in the Fat of Obese Co-twins
The most signiﬁcantly down-regulated pathway in the
obese co-twins was branched chain family amino acid (BCAA)
Table 2. Pathways Up-regulated in the Obese Co-twins
GO Category Pathway Name Nominal
p-Value
Empirical
p-Value
Number of Genes
in Pathway
GO:0019884 Antigen processing and presentation of exogenous antigen 2.99 3 10
 11 0.0001 21
GO:0006954 Inflammatory response 1.16 3 10
 10 0.0001 241
GO:0006959 Humoral immune response 1.31 3 10
 10 0.0001 169
GO:0007626 Locomotory behaviour 1.00 3 10
 9 0.0001 177
GO:0016064 Immunoglobulin mediated immune response 1.06 3 10
 9 0.0001 123
GO:0015629 Actin cytoskeleton 3.30 3 10
 9 0.0001 223
GO:0019882 Antigen presentation 5.02 3 10
 9 0.0001 56
GO:0006935 Chemotaxis 1.26 3 10
 8 0.0001 130
GO:0042330 Taxis 1.26 3 10
 8 0.0001 130
GO:0006968 Cellular defense response 5.88 3 10
 7 0.0001 118
GO:0019838 Growth factor binding 1.57 3 10
 6 0.0002 57
GO:0042591 Antigen processing and presentation of exogenous peptide
antigen via MHC class II
1.86 3 10
 6 0.0001 8
GO:0016197 Endosome transport 1.99 3 10
 6 0.0002 33
GO:0006887 Exocytosis 2.17 3 10
 6 0.0001 80
GO:0051240 Positive regulation of multicellular organismal process 2.34 3 10
 6 0.0003 110
GO:0005178 Integrin binding 2.52 3 10
 6 0.0002 39
GO:0009897 External side of plasma membrane 4.06 3 10
 6 0.0001 52
GO:0005125 Cytokine activity 4.30 3 10
 6 0.0003 220
GO:0008009 Chemokine activity 4.87 3 10
 6 0.0002 42
GO:0042379 Chemokine receptor binding 5.49 3 10
 6 0.0001 43
Nineteen pathways with fewer than 250 members were identified as significantly up-regulated in the adipose tissue of the obese co-twins following co-twin normalization of global
expression values. Results are ranked according to significance (empirical p-values interpreted from the distribution of 10,000 permutation cycles).
doi:10.1371/journal.pmed.0050051.t002
Table 3. Pathways Down-regulated in the Obese Co-twins
GO Category Pathway Name Nominal p-Value Empirical p-Value Number of Genes in Pathway
GO:0009081 Branched chain family amino acid metabolism 5.42 3 10
 8 0.0001 11
GO:0045892 Negative regulation of transcription 4.81 3 10
 7 0.0001 182
GO:0016885 Ligase activity, forming carbon-carbon bonds 2.21 3 10
 6 0.0001 7
GO:009083 Branched chain family amino acid catabolism 6.26 3 10
 6 0.0002 9
GO:0016421 CoA carboxylase activity 7.11 3 10
 6 0.0002 6
GO:0006767 Water-soluble vitamin metabolism 8.29 3 10
 6 0.0004 38
GO:0007517 Muscle development 9.97 3 10
 6 0.0005 156
Seven pathways with fewer than 250 members were identified as significantly downregulated in the adipose tissue of the obese co-twins following co-twin normalization of global
expression values. Results are ranked according to significance (empirical p-values interpreted from the distribution of 10,000 permutation cycles).
doi:10.1371/journal.pmed.0050051.t003
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Pathways behind Acquired Obesitycatabolism (nominal/empirical p ¼ 5.4 3 10
 8/,1.0 3 10
 4),
mostly contributed by the genes encoding the mitochondrial
components of the pathway (Tables 3 and S2). Both genes
common to the degradation of all BCAAs, i.e., leucine,
isoleucine and valine (BCAT2, BCKDHB) and those speciﬁc for
the degradation of leucine (MCCC1, MCCC2, AUH) and valine
(HIBADH, ALDH6A1, ACAD8), were down-regulated in the
obese co-twins. The mean centroid of the BCAA catabolism
pathway correlated negatively with all measures of body fat,
i.e., with liver fat (r¼ 0.56, p¼0.002) (Figure 2), subcutaneous
fat (r¼ 0.49, p¼0.01), and intra-abdominal fat (r¼ 0.47, p¼
0.01). In a multiple regression analysis including these fat
depots, only liver fat remained signiﬁcantly associated with
BCAA catabolism (R
2 ¼ 29%). Further underscoring its
importance, ‘‘BCAA catabolism’’ remained signiﬁcant (b ¼
 0.38, p ¼ 0.018) even after including the four most up- and
down-regulated pathways (from Tables 2 and 3) to explain
liver fat in a multiple regression (R
2 ¼ 63%, p ¼ 0.0008).
Decreased mitochondrial BCAA catabolism was associated
with insulin resistance (correlation of ‘‘BCAA catabolism’’
with fS-insulin r¼ 0.62, p¼0.001, M-value r¼0.52, p¼0.001,
and S-adiponectin r¼0.49, p¼0.011, Figure 2) and low-grade
inﬂammation (high-sensitivity CRP r ¼  0.41, p ¼ 0.005). To
provide some evidence for the biological signiﬁcance of this
ﬁnding at the whole body level, we measured serum
concentrations of a leucine breakdown product, a-ketoiso-
caproate, in plasma and conﬁrmed that lowered BCAA
catabolism activity was paralleled by decreased a-ketoisocap-
roate levels (r ¼ 0.44, p ¼ 0.027). Furthermore, we found in
males that serum leucine and valine as well as total BCAA
(leucine, valine, isoleucine) concentrations were higher in the
plasma of obese than non-obese co-twins (median total BCAA
0.47 lM versus. 0.43 lM, p ¼ 0.025) and correlated
signiﬁcantly with fS-insulin (total BCAA and insulin r ¼
0.50, p ¼ 0.028). This result is consistent with earlier studies
describing high serum BCAAs in obesity [38] and hyper-
insulinemia [39]. These correlations were not found at a
statistically signiﬁcant level in female co-twins.
Energy Metabolism and Cell Differentiation Down-
regulated in the Obese Co-twins
Acquired obesity in twins was associated with a signiﬁcant
down-regulation of the genes encoding the rate-limiting
enzymes in fatty acid synthesis and b-oxidation (Table S2),
and especially interesting was the down-regulation of
mitochondrial acetyl-coenzyme A carboxylase beta (ACACB), an
important regulator of fatty acid oxidation. Lowering of its
transcription was associated with liver fat accumulation (r ¼
 0.55, p ¼ 0.009). Pyruvate carboxylase down-regulation
suggests lowered synthesis of acetyl-CoA. Down-regulation
of the genes encoding enzymes essential for NAD(P) synthesis
(NMNAT2, NMNAT3, visfatin) was associated with down-
regulation of NAD-dependent transcription regulators, such
as SIRT1, 3, and 7 histone deacetylases (HDAC5, SIN3A),
induction of which is linked to calorie restriction and
longevity [40]. Fatty acid synthesis, acetyl-CoA production,
NAD(P) biosynthesis, and BCAA catabolism have been found
to be up-regulated during the differentiation of 3T3-L1
adipocytes [41]. Our opposite ﬁndings would suggest that
adipocyte differentiation is impaired in acquired obesity, a
Figure 2. The Relationships between the Mean Expression of the BCAA catabolism Pathway and Liver Fat, fS-Insulin, Whole Body Insulin Sensitivity (the
M-value), and fS-Adiponectin
doi:10.1371/journal.pmed.0050051.g002
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Pathways behind Acquired Obesityﬁnding endorsed by reduced PPARG expression in the obese
co-twins.
We also saw in our study sample that enlargement of fat cell
size, an indirect sign of poor differentiation, was associated
with down-regulation of the pathways for negative regulation
of transcription (r¼ 0.60), water-soluble vitamin metabolism
(r¼ 0.59), and muscle development (r¼ 0.62) (all p , 0.001),
which involve several differentiation-enhancing factors.
Within twin pairs, increased effects were seen on these
pathways in twins with greater obesity discordance, but they
were not all statistically signiﬁcant. The larger the BMI
discordance, the greater the down-regulation of BCAA
catabolism (r ¼  0.42, p ¼ 0.16), water-soluble vitamin
metabolism (r ¼  0.64, p ¼ 0.018), and muscle development
(r ¼  0.73, p ¼ 0.0050). For other pathways, similar, but
nonsigniﬁcant results were observed. Furthermore, the great-
er the increase in the BMI discordance from age 16 to young
adulthood, the larger the within-pair down-regulation of, e.g.,
the BCAA catabolism in fat (r ¼  0.62, p ¼ 0.025).
Mitochondrial DNA Copy Number in Fat Decreased in the
Obese Co-twins
The mtDNA sequences of fat showed no evidence for
heteroplasmy in co-twins, nor potentially obesity-associated
sequence changes between obese and non-obese co-twins in
fat or in leukocytes (Figure S1). However, the obese co-twins
had a signiﬁcant reduction of their fat mtDNA copy number,
to 53% of that in the non-obese co-twins (p¼0.033, Table 1).
Conﬁrming the effects of acquired obesity on lowering of fat
mtDNA copy number, we analyzed the mtDNA copy number
from seven MZ twin pairs concordant for body weight
(median BMI for twin A 24.6 kg/m
2 versus twin B 25.4 kg/
m
2). Their median mtDNA copy numbers were similar, 2,077
versus 2,041, p ¼ 0.87. The mtDNA copy numbers in
leukocytes were similar in all twin groups.
Amino acid synthesis is linked to energy metabolism, and
decreased BCAA catabolism could reﬂect reduced oxidative
energy production caused by low mtDNA. However, mtDNA
copy number (p . 0.1) did not solely explain variations in
liver fat, fS-insulin and the M value in multiple regression
analyses where BCAA catabolism (p , 0.01) was used as the
other explanatory variable. This inability of mtDNA loss to
explain in full the decreased catabolism of BCAAs suggests
that the metabolic defects of fat related to acquired obesity
would not be solely attributed to the reduced number of
mtDNA copies. However, this apparent mitochondrial defect
is likely to initiate multiple signaling pathways, some critical
ones likely involved in BCAA metabolism.
Longitudinal Data on an Obese Male Twin
While this study design was designed to be purely cross-
sectional, we obtained a second measurement of one of the
obese male twins, who had gained 10.7 kg (from 93.2 to 103.9
kg) at a re-visit after 3.3 y. We found further pathological
changes that were in line with those observed in the whole
dataset between all the co-twins. The BMI of this obese twin
increased from 28.4 to 32.0 kg/m
2, with a concomitant
increase in all other body fat parameters. Most notable was
the 4-fold increase in liver fat (from 2.5% to 10.4%). The M-
value describing insulin sensitivity decreased from 7.3 to 3.8
mg kg fat-free mass
 1 min
 1, and serum insulin increased
from 12 to 15.3 mU/l. Inﬂammatory pathways of fat were
more up-regulated in the advanced state of obesity, e.g., the
mean centroid of the inﬂammatory response pathway
increased 70%. Mitochondrial DNA copy number in fat
decreased by 44% and serum BCAA concentrations increased
from 0.49 to 0.55 lM and those of leucine from 0.14 to 0.17
lM.
Discussion
Our carefully phenotyped MZ twins most discordant for
obesity represent an ideal model to explore the effects of
acquired human obesity independent of genetic factors. By
constructing networks of global transcript proﬁles in sub-
cutaneous fat biopsies, we identiﬁed several fundamental
pathways with high relevance for obesity and its related
insulin resistance (Figure 3). Our data suggest that obesity
that is already in its early stages in healthy young adults is
characterized by marked inﬂammation of adipose tissue,
signiﬁcantly reduced mitochondrial DNA copy number, and
disturbed mitochondrial energy metabolism—statistically
most signiﬁcantly, the decreased catabolism of insulin
secretion–enhancing BCAAs. These impairments correlated
with the critical clinical measures of obesity: liver fat
accumulation, reduced whole-body insulin sensitivity, hyper-
insulinemia, and hypoadiponectinemia.
The observed impairments in adipose tissue function could
be associated with insulin resistance by at least the following
mechanisms: (1) Inﬂammation in fat and a direct action of
cytokines or other mediators on the insulin signaling cascade
[42], (2) decline in mitochondrial DNA content or function
[43], and (3) diminished adipocyte differentiation within
subcutaneous adipose tissue and subsequent increase in
ectopic fat deposition [11,12].
A wide range of inﬂammatory cascades, both humoral and
cellular mediators, seemed to be activated in the obese co-
twins’ fat. In line with previous studies [6], the major over-
expressed innate inﬂammatory component was related to
macrophages. These cells act as scavengers phagocytosing
adipose debris [8] and as antigen-presenting cells activating
the adaptive immune system. Another up-regulated pathway
in obese co-twins involved antigen presentation via MHC
class II molecules. This result, together with signs of activation
of lymphocytes and the complement system, suggest a
widespread induction of previously unrecognized dimensions
of the inﬂammatory response in obesity. In addition, comple-
ment component 3a receptor 1 (C3ar1), up-regulated in the obese
co-twins, is among the three new genes with causal relation-
ships for obesity in an elegant study in rodents integrating
gene expression and DNA variation [44].
A whole range of local and humoral mediators are known
to inhibit insulin signaling [42]. Additionally, recent studies
show that speciﬁc proinﬂammatory lipid molecules, the
lysophosphatidylcholines (LPCs), may impair insulin signaling
at the level of insulin receptor substrate-1 (IRS1) and Akt/
protein kinase C [45]. LPCs, major components of oxidized
low-density lipoprotein (LDL), are phospholipase A2-gener-
ated hydrolysis products of phosphatidylcholines, which are
connected with the up-regulation of LDL-associated phos-
pholipase A2 (PLA2G7) observed in the fat of the obese twins
in this study. Furthermore, LPCs activate RhoA GTPases [46],
MCP1, and other chemokines [47], which were also up-
regulated in this study’s obese co-twins. In our previous study,
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the obese co-twins, and were associated with lower insulin
sensitivity [48]. This observation supports the view that LPCs
and possibly other lysophospholipids may act as triggers of
inﬂammation in adipose tissue and play a role in obesity-
related insulin resistance.
Our ﬁnding that the most over-expressed (5.9-fold) gene in
the adipose tissue of the obese co-twins was the inﬂammatory
cytokine osteopontin (SPP1, also termed OPN), involved in
the recruitment of macrophages, is of great interest. During
the review process of this article, Nomiyama and colleagues
published their ﬁndings (in a mouse model of diet-induced
Figure 3. Summary of Findings and Postulated Mechanisms and How They Associate with the Clinical Progression of Obesity-Related Pathologies
Obesity already in its early stages in healthy young adults is characterized by marked inflammation of adipose tissue, significantly reduced copy number
of mitochondrial DNA, and disturbed mitochondrial energy metabolism—most importantly decreased BCAA catabolism. Down-regulation of
mitochondrial energy metabolism and BCAA catabolism is related to impaired differentiation and storage capacity of subcutaneous fat. Fat deposition
to the liver increases, which is associated with insulin resistance and hyperinsulinemia. Insulin resistance may impair BCAA catabolism through
decreased uptake of amino acids to cells and, as a feedback mechanism, serum BCAA concentrations increase and induce pancreatic insulin secretion.
Inflammation may also cause insulin resistance through other mechanism, such as direct action of cytokines or other mediators.
doi:10.1371/journal.pmed.0050051.g003
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insulin resistance [49]. Their results suggest that SPP1 plays a
key role in the recruitment of macrophages into the adipose
tissue in obese mice and thus in the development of insulin
resistance. Secretion of SPP1 was increased during obesity
and, unlike in wild-type mice, animals lacking SPP1 were
protected from developing insulin resistance despite diet-
induced obesity. The authors also showed that SPP1
expression decreased during the differentiation of 3T3-L1
preadipocytes, suggesting that alongside the decrease in
PPARc expression observed here, the dramatic increase in
SPP1 expression is yet another marker for poor differ-
entiation of adipocytes in obesity. The over-expression of
SPP1 in obese adipose tissue—here to our knowledge
reported for the ﬁrst time in humans—is an important
observation in understanding the development of insulin
resistance associated with obesity.
We found considerable depletion of mtDNA in adipose
tissue of obese co-twins; to our knowledge this is the ﬁrst
ﬁnding of its kind in humans. Such a decline in the mtDNA
content of fat cells may decrease the maximal capacity for
oxidative phosphorylation, i.e., utilization of fat for energy
production. Our study does not yet answer the question of
whether mtDNA depletion is a primary event in acquired
obesity or whether it is secondary and reactive to, for
example, inﬂammation. However, such a remarkable decrease
in mtDNA copy number would have a considerable impact on
energy metabolism of fat tissue. Supporting our ﬁndings,
patients with mutations in polymerase gamma, the mtDNA
replicative polymerase, show partial mtDNA depletion and
obesity [50]. Furthermore, in our weight-concordant control
MZ pairs, the mtDNA copy number levels were nearly
identical. Taken together, these results strongly suggest that
mtDNA depletion in our study’s obese co-twins is weight-
dependent. Longitudinal data accessible to us for one obese
male further supported this suggestion: after this twin’s
weight increased by 10 kg within 3 y, mtDNA copy number in
his fat tissue declined by 44%.
MtDNA copy number is under nuclear control and can be
regulated by proteins of mtDNA maintenance and by
cytoplasmic nucleoside pools. Since MZ twins have identical
nuclear genes, the depletion of mtDNA we saw in obese co-
twins suggests that mtDNA levels in the adipose tissue
respond to environmental factors, such as nutrition and
exercise. Such an effect has been documented in human
skeletal muscle [51]. Genetic factors [18] and age [52] may also
inﬂuence mtDNA levels and capacity for oxidative energy
production. However, controversy remains over whether low
mitochondrial oxidative capacity can be accounted for by
reduced overall mitochondrial mass or by mitochondrial
dysfunction [53,54]. The role of mtDNA levels and mitochon-
drial dysfunction in obesity has not, to our knowledge, been
shown in human adipose tissue before. Here we demonstrate
that acquired obesity, at an early stage and independent of
genetic variation or age, is associated with signiﬁcant
decreases in mtDNA copy number in fat, together with low
expression of transcripts involved in mitochondrial oxidative
energy metabolism and BCAA catabolism.
Observations in animal models of obesity (ob/ob mouse) and
type 2 diabetes (db/db mouse) have recently shown a reduction
in the mtDNA content of white adipocytes concomitant with
smaller mitochondrial size, disturbed mitochondrial mor-
phology, and reduced respiration rates [55]. This pattern was
observed only in adipose tissue, not in skeletal muscle or liver.
In another study, treatment with the insulin sensitivity-
enhancing drug rosiglitazone reversed the dysmorphologic
features of ob/ob mouse mitochondria and mitochondrial
protein proﬁle [19]. These observations emphasize the role of
adipose tissue, and especially of the associated mitochondria,
in the development of insulin resistance and other obesity-
associated pathologies.
Down-regulation of BCAA catabolism in subcutaneous
adipose tissue was associated with liver fat accumulation, the
mechanisms of which may involve not only reduced mito-
chondrial respiration in the existing adipocytes, but also
reduced differentiation and formation of new adipocytes
within the subcutaneous sites, which shifts lipid storage into
peripheral tissues. BCAA catabolism is normally activated
during adipocyte differentiation, together with the key
transcription factor PPARc and molecules of oxidative
energy production (acetyl-CoA utilization and NAD(P) bio-
synthesis) [41], all of which were coordinately down-regulated
in our study’s obese co-twins. Impaired adipogenesis, togeth-
er with impaired mitochondrial biogenesis in subcutaneous
adipose tissue, could connect obesity to liver fat accumu-
lation and to the development of type 2 diabetes [11,12].
Following the clue provided by the transcript proﬁles in
fat, we searched for signs of the systemic effects of low
adipose tissue mitochondrial BCAA catabolism. The decrease
in BCAA catabolism activity was associated with low serum
concentrations of leucine ketoacids. High serum BCAA
(especially leucine) concentrations were associated with
obesity and hyperinsulinemia in the males in our study,
which is in line with earlier studies suggesting that BCAAs
may augment insulin secretion from the pancreas in insulin-
resistant states [38,39]. Recent studies in rat adipocytes have
identiﬁed that BCAAs act both as triggers of insulin secretion
and also as important players in the augmentation of insulin
signaling through the mTOR (mammalian target of rapamy-
cin) and phosphatidylinositol 3-kinase signaling pathways
[56]. Thus, normal BCAA metabolism may be critical for the
maintenance of an appropriate insulin response. We propose
that reduced mitochondrial BCAA catabolism (possibly as a
consequence of low mtDNA levels), inhibition of adipose
tissue differentiation, increased liver fat accumulation, and
stimulation of insulin secretion by high serum BCAA levels
may explain part of the well-documented association between
fatty liver and hyperinsulinemia during the development of
insulin resistance syndrome [57].
An additional novel ﬁnding in our study was the down-
regulation of several NAD
þ-dependent histone deacetylases
or their associated proteins (e.g., HDAC5, SIN3, SIRT1, SIRT3,
and SIRT7) in the fat tissue of the obese co-twins. Sirtuins
(SIRTs) have been shown to mediate the response to caloric
restriction, and their overexpression mimics this response in
disease models (SIR2 in C. elegans), leading to an extended life
span. Furthermore, they also regulate insulin-signaling and
energy metabolic pathways [40]. In humans, SIRT1 gene
expression in skeletal muscle has been shown to increase in
caloric restriction with or without exercise and in vitro by
adiponectin treatment [58]. Our ﬁndings of the coordinated
down-regulation of sirtuin expression in obese-human fat
are, to our knowledge, ﬁrst of its kind, and may be a
consequence of decreased NAD synthesis and reduced energy
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levels and increased NADH and nicotinamide levels could
inhibit the sirtuins, thus initiating a cascade of events through
numerous pathways that would (1) decrease transcription of
genes for mitochondrial biogenesis and potentially reduce
mtDNA copy number; and (2) decrease lipolysis through
PPARs, thus promoting obesity [40].
The MZ co-twin control study represents perhaps the best
controlled study design available in humans because of the
complete or close match for genes, age, gender, and
intrauterine and childhood environment. However, when
used retrospectively as done here, it does not solve the
problem of direction of causation. For this reason, we include
some results from one obese study participant who had
gained weight upon a follow-up visit. These data, although
they essentially amount to a case report, do show convinc-
ingly a further pathological progression in the same measures
identiﬁed as differing between the obese and non-obese
twins. Despite the limited sample size, this, in addition to the
trend for increased effects in twins with greater obesity
discordance, lend support to the notion that the changes
identiﬁed in this limited study sample are indeed sequelae,
not proximal causes of obesity.
This study provides evidence for the contribution of lifestyle
to the metabolic disturbances in obesity. However, it does not
devalue the effects of genes. The fact that it was extremely
difﬁcult to ﬁnd young, healthy MZ twins with large weight
differences (14 twin pairs out of 2,453) itself suggests a genetic
basis for obesity. The large differences in BMI within these
most-discordant pairs may have arisen because of the presence
of ‘‘environmental sensitivity/variability’’ genes that make
these individuals particularly susceptible to environmental
variation (such as diet and exercise), whereas other pairs who
were concordant for BMI may carry alleles that render them
relatively impervious to dietary or physical activity patterns.
While the contribution of possible epigenetic changes [59]
cannot be conclusively ruled out, they seem unlikely to explain
this adult discordance, as all twins analyzed in the current
study exhibited remarkably similar development of BMI until
the onset of obesity in their early adulthood [23].
In summary, this study identiﬁed several changes in
transcript proﬁles of adipose tissue early in acquired obesity
by using the obesity-discordant MZ co-twin control design
that allows full control for genomic sequence variations, a
signiﬁcant confounder in most studies comparing obese and
non-obese participants. Our results highlight the metabolic
plasticity and alterations of human adipose tissue. Our most
critical ﬁndings were that, in the fat of obese co-twins
compared to their non-obese counterparts, (1) mtDNA
content was reduced, (2) mitochondrial energy production
pathways were down-regulated along with adipocyte differ-
entiation within subcutaneous adipose tissue, and (3) increase
in ectopic fat deposition was subsequently increased. These
events probably represent important drivers of insulin
resistance, hyperinsulinemia, and accumulation of liver fat,
pathognomonic characteristics of obesity acquired already in
the young. It is likely that proper management of obesity,
primarily by lifestyle changes, and perhaps with a new
generation of therapies directed at several targets in
mitochondrial biogenesis pathways, will correct these abnor-
malities and favorably modify the risk, course, and outcome
of diabetes and cardiovascular diseases.
Supporting Information
Figure S1. Sequence Variants in mtDNA Identiﬁed in the Most
Discordant Twin Pair with a BMI Difference of 10.1 kg/m
2
Columns 1 and 2 show variant position in reference sequence
AC_000021.1 and corresponding reference nucleotide. Columns 3 to
6 show variant genotypes of the co-twins from leukocytes and fat.
Heteroplasmy found at position 311 was present in both leukocytes
and fat. Mitochondrial DNA sequences from blood leukocytes and fat
samples were identical in all twin pairs sequenced (unpublished data).
Found at doi:10.1371/journal.pmed.0050051.sg001 (1.9 MB TIF).
Table S1. Pathways Up-regulated in the Obese Co-twins: Elaborated
Found at doi:10.1371/journal.pmed.0050051.st001 (100 KB DOC).
Table S2. Pathways Down-regulated in the Obese Co-twins: Elaborated
Found at doi:10.1371/journal.pmed.0050051.st002 (49 KB DOC).
Text S1. Supplemental Methods
Found at doi:10.1371/journal.pmed.0050051.sd001 (117 KB DOC).
Accession Numbers
The microarray data reported in this manuscript have been deposited
in ArrayExpress (http://www.ebi.ac.uk/), accession number E-MEXP-
1425.
Acknowledgments
The authors wish to thank all the volunteers, and Katja Tuominen,
Erjastiina Heikkinen, Mia Urjansson, Massimiliano Gentile, and
Gopalacharyulu Peddinti for their skillful help in the study.
Author contributions. AR initiated the concept of the study and
KHP, AR, HYJ, JK, and LP designed it. JK was responsible for
collecting the study base from which the discordant pairs were
selected. KHP conducted the trial and AR, HYJ, and JK supervised its
progression. LP carried the overall responsibility of the study design
of genome-wide transcription and pathway analyses conducted by JN
and JS. AS and LP supervised the mitochondrial sequence analyses
performed by PE, HK, and AG. TS and MO analyzed serum BCAAs
and their ketoacids. KHP and JS performed the statistical analyses. All
authors contributed to interpretation of the data and KHP, JN, AR,
MO, and LP, wrote the manuscript.
Competing Interests. The authors have declared that no competing
interests exist.
Funding. This study was supported by the US National Institute on
Alcohol Abuse and Alcoholism (grants AA-08315, AA-00145 and AA-
12502), the European Union Fifth Framework Program GenomEUt-
win (http://www.genomeutwin.org/) (QLG2-CT-2002–01254), the
Academy of Finland (Grant 44069, 100499 and 201461), the Academy
of Finland Centre of Excellence in Complex Disease Genetics and in
Mitochondrial Disease and Aging (FinMIT), the Nordic Center of
Excellence in Disease Genetics, Sigrid Juselius Foundation, Biocen-
trum Helsinki Foundation and Helsinki University Central Hospital
grants. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
References
1. Muoio DM, Newgard CB (2006) Obesity-related derangements in metabolic
regulation. Annu Rev Biochem 75: 367–401.
2. Schadt EE, Lum PY (2006) Thematic review series: systems biology
approaches to metabolic and cardiovascular disorders. Reverse engineering
gene networks to identify key drivers of complex disease phenotypes. J
Lipid Res 47: 2601–2613.
3. Nair S, Lee YH, Rousseau E, Cam M, Tataranni PA, et al. (2005) Increased
expression of inﬂammation-related genes in cultured preadipocytes/
stromal vascular cells from obese compared with non-obese Pima Indians.
Diabetologia 48: 1784–1788.
4. Lee YH, Nair S, Rousseau E, Allison DB, Page GP, et al. (2005) Microarray
proﬁling of isolated abdominal subcutaneous adipocytes from obese vs
non-obese Pima Indians: increased expression of inﬂammation-related
genes. Diabetologia 48: 1776–1783.
5. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, et al. (2004) Weight
loss regulates inﬂammation-related genes in white adipose tissue of obese
subjects. FASEB J 18: 1657–1669.
6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003)
Obesity is associated with macrophage accumulation in adipose tissue. J
Clin Invest 112: 1796–1808.
7. Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic
switch in adipose tissue macrophage polarization. J Clin Invest 117: 175–184.
PLoS Medicine | www.plosmedicine.org March 2008 | Volume 5 | Issue 3 | e51 0481
Pathways behind Acquired Obesity8. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, et al. (2005) Adipocyte
death deﬁnes macrophage localization and function in adipose tissue of
obese mice and humans. J Lipid Res 46: 2347–2355.
9. Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K (2007)
Macrophage-secreted factors impair human adipogenesis: involvement of
proinﬂammatory state in preadipocytes. Endocrinology 148: 868–877.
10. Yang X, Jansson PA, Nagaev I, Jack MM, Carvalho E, et al. (2004) Evidence
of impaired adipogenesis in insulin resistance. Biochem Biophys Res
Commun 317: 1045–1051.
11. Heilbronn L, Smith SR, Ravussin E (2004) Failure of fat cell proliferation,
mitochondrial function and fat oxidation results in ectopic fat storage,
insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab
Disord 28 Suppl 4: S12–S21.
12. Lelliott C, Vidal-Puig AJ (2004) Lipotoxicity, an imbalance between
lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab
Disord 28 Suppl 4: S22–S28.
13. Waki H, Park KW, Mitro N, Pei L, Damoiseaux R, et al. (2007) The small
molecule harmine is an antidiabetic cell-type-speciﬁc regulator of
PPARgamma expression. Cell Metab 5: 357–370.
14. Bogacka I, Xie H, Bray GA, Smith SR (2005) Pioglitazone induces
mitochondrial biogenesis in human subcutaneous adipose tissue in vivo.
Diabetes 54: 1392–1399.
15. Yki-Ja ¨rvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106–1118.
16. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al.
(2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation
are coordinately downregulated in human diabetes. Nat Genet 34: 267–273.
17. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, et al. (2003) Coordinated
reduction of genes of oxidative metabolism in humans with insulin
resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad
Sci U S A 100: 8466–8471.
18. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired
mitochondrial activity in the insulin-resistant offspring of patients with
type 2 diabetes. N Engl J Med 350: 664–671.
19. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, et al. (2004)
Mitochondrial remodeling in adipose tissue associated with obesity and
treatment with rosiglitazone. J Clin Invest 114: 1281–1289.
20. Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, et al. (2006) TNF-alpha
downregulates eNOS expression and mitochondrial biogenesis in fat and
muscle of obese rodents. J Clin Invest 116: 2791–2798.
21. Kaprio J, Pulkkinen L, Rose RJ (2002) Genetic and environmental factors in
health-related behaviors: studies on Finnish twins and twin families. Twin
Res 5: 366–371.
22. Pietila ¨inen KH, Rissanen A, Kaprio J, Ma ¨kimattila S, Ha ¨kkinen AM, et al.
(2005) Acquired obesity is associated with increased liver fat, intra-
abdominal fat, and insulin resistance in young adult monozygotic twins.
Am J Physiol Endocrinol Metab 288: E768–E774.
23. Pietila ¨inen KH, Rissanen A, Laamanen M, Lindholm AK, Markkula H, et al.
(2004) Growth patterns in young adult monozygotic twin pairs discordant
and concordant for obesity. Twin Res 7: 421–429.
24. Kannisto K, Pietila ¨inen KH, Ehrenborg E, Rissanen A, Kaprio J, et al. (2004)
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose
tissue is associated with acquired obesity and features of insulin resistance:
studies in young adult monozygotic twins. J Clin Endocrinol Metab 89:
4414–4421.
25. Gertow K, Pietila ¨inen KH, Yki-Ja ¨rvinen H, Kaprio J, Rissanen A, et al.
(2004) Expression of fatty-acid-handling proteins in human adipose tissue
in relation to obesity and insulin resistance. Diabetologia 47: 1118–1125.
26. Pietila ¨inen KH, Kannisto K, Korsheninnikova E, Rissanen A, Kaprio J, et al.
(2006) Acquired obesity increases CD68 and TNF-falphag and decreases
adiponectin gene expression in adipose tissue. A study in monozygotic
twins. J Clin Endocrinol Metab 91: 2776–2781.
27. Pietila ¨inen KH, Bergholm R, Rissanen A, Kaprio J, Ha ¨kkinen AM, et al.
(2006) Effects of acquired obesity on endothelial function in monozygotic
twins. Obesity (Silver Spring) 14: 826–837.
28. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a
method for quantifying insulin secretion and resistance. Am J Physiol 237:
E214–E223.
29. Pakkasjarvi N, Gentile M, Saharinen J, Honkanen J, Herva R, et al. (2005)
Indicative oligodendrocyte dysfunction in spinal cords of human fetuses
suffering from a lethal motoneuron disease. J Neurobiol 65: 269–281.
30. Wick N, Saharinen P, Saharinen J, Gurnhofer E, Steiner CW, et al. (2007)
Transcriptomal comparison of human dermal lymphatic endothelial cells
ex vivo and in vitro. Physiol Genomics 28: 179–192.
31. Pakkasjarvi N, Kerosuo L, Nousiainen H, Gentile M, Saharinen J, et al.
(2007) Neural precursor cells from a fatal human motoneuron disease
differentiate despite aberrant gene expression. Dev Neurobiol 67: 270–284.
32. Kiialainen A, Veckman V, Saharinen J, Paloneva J, Gentile M, et al. (2007)
Transcript proﬁles of dendritic cells of PLOSL patients link demyelinating
CNS disorders with abnormalities in pathways of actin bundling and
immune response. J Mol Med 85: 971–983.
33. Rao JNK, Scott AJ (1984) On chi-squared tests for multiway contingency
tables with cell proportions estimated from survey data. Annals of Statistics
12: 46–60.
34. Pietila ¨inen KH, Kaprio J, Borg P, Plasqui G, Yki-Ja ¨rvinen H, et al. (2007)
Physical inactivity and obesity: A vicious circle. Obesity (Silver Spring) In
press:
35. Wang S, Yehya N, Schadt EE, Wang H, Drake TA, et al. (2006) Genetic and
genomic analysis of a fat mass trait with complex inheritance reveals
marked sex speciﬁcity. PLoS Genet 2: e15. doi:10.1371/journal.pgen.
0020015
36. Boomsma D, Busjahn A, Peltonen L (2002) Classical twin studies and
beyond. Nat Rev Genet 3: 872–882.
37. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, et al.
(2002) Osteopontin–a molecule for all seasons. QJM 95: 3–13.
38. Felig P, Marliss E, Cahill GF Jr. (1969) Plasma amino acid levels and insulin
secretion in obesity. N Engl J Med 281: 811–816.
39. Floyd JC Jr., Fajans SS, Knopf RF, Conn JW (1963) Evidence that insulin
release is the mechanism for experimentally induced leucine hypoglycemia
in man. J Clin Invest 42: 1714–1719.
40. Yang T, Sauve AA (2006) NAD metabolism and sirtuins: metabolic
regulation of protein deacetylation in stress and toxicity. AAPS J 8:
E632–E643.
41. Hackl H, Burkard TR, Sturn A, Rubio R, Schleiffer A, et al. (2005) Molecular
processes during fat cell development revealed by gene expression proﬁling
and functional annotation. Genome Biol 6: R108.
42. Wellen KE, Hotamisligil GS (2005) Inﬂammation, stress, and diabetes. J Clin
Invest 115: 1111–1119.
43. Petersen KF, Shulman GI (2006) Etiology of insulin resistance. Am J Med
119: S10–S16.
44. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, et al. (2005) An integrative
genomics approach to infer causal associations between gene expression
and disease. Nat Genet 37: 710–717.
45. Motley ED, Kabir SM, Gardner CD, Eguchi K, Frank GD, et al. (2002)
Lysophosphatidylcholine inhibits insulin-induced Akt activation through
protein kinase C-alpha in vascular smooth muscle cells. Hypertension 39:
508–512.
46. Huang F, Subbaiah PV, Holian O, Zhang J, Johnson A, et al. (2005)
Lysophosphatidylcholine increases endothelial permeability: role of
PKCalpha and RhoA cross talk. Am J Physiol Lung Cell Mol Physiol 289:
L176–L185.
47. Murugesan G, Sandhya Rani MR, Gerber CE, Mukhopadhyay C, Ransohoff
RM, et al. (2003) Lysophosphatidylcholine regulates human microvascular
endothelial cell expression of chemokines. J Mol Cell Cardiol 35: 1375–
1384.
48. Pietila ¨inen KH, Sysi-Aho M, Rissanen A, Seppala-Lindroos A, Yki-Ja ¨rvinen
H, et al. (2007) Acquired obesity is associated with changes in the serum
lipidomic proﬁle independent of genetic effects - a monozygotic twin
study. PLoS ONE 2: e218. doi:10.1371/journal.pone.0000218
49. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, et al. (2007)
Osteopontin mediates obesity-induced adipose tissue macrophage inﬁltra-
tion and insulin resistance in mice. J Clin Invest 117: 2877–2888.
50. Hakonen AH, Heiskanen S, Juvonen V, Lappalainen I, Luoma PT, et al.
(2005) Mitochondrial DNA polymerase W748S mutation: a common cause
of autosomal recessive ataxia with ancient European origin. Am J Hum
Genet 77: 430–441.
51. Hood DA, Irrcher I, Ljubicic V, Joseph AM (2006) Coordination of
metabolic plasticity in skeletal muscle. J Exp Biol 209: 2265–2275.
52. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, et al. (2003)
Mitochondrial dysfunction in the elderly: possible role in insulin resistance.
Science 300: 1140–1142.
53. Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, et al. (2007)
Patients with type 2 diabetes have normal mitochondrial function in
skeletal muscle. Diabetologia 50: 790–796.
54. Holloway GP, Thrush AB, Heigenhauser GJ, Tandon NN, Dyck DJ, et al.
(2007) Skeletal muscle mitochondrial FAT/CD36 and palmitate oxidation
are not decreased in obese women. Am J Physiol Endocrinol Metab 292:
E1782–E1789.
55. Choo HJ, Kim JH, Kwon OB, Lee CS, Mun JY, et al. (2006) Mitochondria are
impaired in the adipocytes of type 2 diabetic mice. Diabetologia 49: 784–
791.
56. Hinault C, Van Obberghen E, Mothe-Satney I (2006) Role of amino acids in
insulin signaling in adipocytes and their potential to decrease insulin
resistance of adipose tissue. J Nutr Biochem 17: 374–378.
57. Yki-Ja ¨rvinen H, Westerbacka J (2005) The fatty liver and insulin resistance.
Curr Mol Med 5: 287–295.
58. Civitarese AE, Carling S, Heilbronn LK, Hulver MH, Ukropcova B, et al.
(2007) Calorie restriction increases muscle mitochondrial biogenesis in
healthy humans. PLoS Med 4: e76. doi:10.1371/journal.pmed.0040076
59. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. (2005) Epigenetic
differences arise during the lifetime of monozygotic twins. Proc Natl Acad
Sci U S A 102: 10604–10609.
PLoS Medicine | www.plosmedicine.org March 2008 | Volume 5 | Issue 3 | e51 0482
Pathways behind Acquired ObesityEditors’ Summary
Background. Around the world, the proportion of people who are obese
(people with an unhealthy amount of body fat) is increasing. In the US,
for example, 1 adult in 7 was obese in the mid 1970s. That is, their body
mass index (BMI)—their weight in kilograms divided by their height in
meters squared—was more than 30. Nowadays, 1 US adult in 3 has a BMI
this high and, by 2025, it is predicted that 1 in 2 will be obese. This
obesity epidemic is being driven by lifestyle changes that encourage the
over-consumption of energy-rich foods and discourage regular physical
activity. The resultant energy imbalance leads to weight gain (the excess
energy is stored as body fat or adipose tissue) and also triggers
numerous metabolic changes, alterations in the chemical processes that
convert food into the energy and various substances needed to support
life. These obesity-related metabolic changes increase a person’s risk of
developing adverse health conditions such as diabetes, a condition in
which dangerously high levels of sugar from food accumulate in the
blood.
Why Was This Study Done? The changes in human fat in obesity have
not been completely understood, although the abnormal metabolism of
adipose tissue is increasingly seen as playing a critical part in excessive
weight gain. It has been very difficult to decipher which molecular and
metabolic changes associated with obesity are the result of becoming
obese, and which might contribute towards the acquisition of obesity in
humans in the first place. To discover more about the influence of
environment on obesity-induced metabolic changes, the researchers in
this study have investigated these changes in pairs of genetically
identical twins.
What Did the Researchers Do and Find? The researchers recruited 14
pairs of genetically identical Finnish twins born between 1975 and 1979
who were ‘‘obesity discordant’’—that is, one twin of each pair had a BMI
of about 25 (not obese); the other had a BMI of about 30 (obese). The
researchers took fat and blood samples from each twin, determined the
insulin sensitivity of each, and measured the body composition and
various fat stores of each. They found that the obese twins had more
subcutaneous, intra-abdominal, and liver fat and were less insulin
sensitive than the non-obese twins. Insulin sensitivity correlated with the
amount of liver fat. Analysis of gene expression in the fat samples
showed that 19 gene pathways (mainly inflammatory pathways) were
expressed more strongly (up-regulated) in the obese twins than the non-
obese twins, whereas seven pathways were down-regulated. The most
highly down-regulated pathway was a mitochondrial pathway involved
in amino acid breakdown, but mitochondrial energy metabolism
pathways were also down-regulated. Finally, mitochondrial DNA copy
number in fat was reduced in the obese twins by nearly half, a novel
observation that could partly account for the obesity-induced metabolic
defects of these individuals.
What Do These Findings Mean? These and other findings identify
several pathways that are involved in the development of obesity and
insulin resistance. In particular, they suggest that changes in mitochon-
drial energy production pathways and in mitochondrial amino acid
metabolism pathways could play important roles in the development of
obesity and of insulin resistance and in the accumulation of liver fat even
in young obese people. The study design involving identical twins has
here produced some evidence for aberrations in molecules critical for
acquired obesity. The results suggest that careful management of
obesity by lifestyle changes has the potential to correct the obesity-
related metabolic changes in fat that would otherwise lead to diabetes
and other adverse health conditions in obese individuals. In addition,
they suggest that the development of therapies designed to correct
mitochondrial metabolism might help to reduce the illnesses associated
with obesity.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050051.
  The MedlinePlus encyclopedia has pages on obesity and diabetes (in
English and Spanish)
  The US Centers for Disease Control and Prevention provides
information on all aspects of obesity (in English and Spanish)
  The UK National Health Service’s health Web site (NHS Direct) provides
information about obesity
  The International Obesity Taskforce provides information about
preventing obesity and on diabetes and obesity
  The UK Foods Standards Agency and the United States Department of
Agriculture provide online tools and useful advice about healthy
eating for adults and children
  Information is available for patients and carers from the US National
Diabetes Information Clearinghouse on diabetes, including informa-
tion on insulin resistance
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